AJTMH ASTMH Job Mart
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Am. J. Trop. Med. Hyg., 72(4), 2005, pp. 421-422
Copyright © 2005 by The American Society of Tropical Medicine and Hygiene

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (8)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by SOTO, J.
Right arrow Articles by BERMAN, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by SOTO, J.
Right arrow Articles by BERMAN, J.
Related Collections
Right arrow Leishmaniasis

SHORT REPORT: EFFICACY OF PENTAVALENT ANTIMONY FOR TREATMENT OF COLOMBIAN CUTANEOUS LEISHMANIASIS

J. SOTO, J. TOLEDO, J. VEGA, AND J. BERMAN
Consorcio de Investigaciones Bioclínicas, Bogota, Colombia; North Bethesda, Maryland

 

ABSTRACT

Two hundred twenty-six consecutive adult patients with cutaneous leishmaniasis in Colombia were treated with Glucantime and 81% were cured. The 19% who failed treatment had received a statistically significant lower total amount of antimony (354 mg/kg) than those who were cured (405 mg/kg) (P = 0.002). Thirty-nine of the failures were re-treated with Glucantime and 59% were cured. This large experience on initial and re-treatment cure rates probably represents the values found in clinical practice. In this series, parasite resistance may have been induced by the relatively low initial dose of antimony administered to some patients.

Received February 4, 2004. Accepted for publication May 5, 2004.

Financial support: This study was supported by the AB Foundation.

Authors’ addresses: J. Soto, J. Toledo, and J. Vega, Consorcio de Investigaciones Bioclínicas, Calle 60 A 5-54, Suite 201, Bogota, Colombia. J. Berman, 6205 Poindexter Lane, North Bethesda, MD 20852, Telephone/Fax: 301-230-7138/0427, E-mail: JBe9320457{at}aol.com.

Reprint requests: J. Soto, Consorcio de Investigaciones Bioclínicas, Calle 60 A 5-54, Suite 201, Bogota, Colombia, Telephone: 57-1-348-2171, Fax: 57-1-347-6093, E-mail: Jaime.Soto{at}medplus.org.co.




This article has been cited by other articles:


Home page
 Infect. Immun.Home page
B. N. Thomas and L. U. Buxbaum
Fc{gamma}RIII Mediates Immunoglobulin G-Induced Interleukin-10 and Is Required for Chronic Leishmania mexicana Lesions
Infect. Immun., February 1, 2008; 76(2): 623 - 631.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2005 by the American Society of Tropical Medicine and Hygiene.